Previous 10 | Next 10 |
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement...
2023-09-14 13:39:25 ET Gainers: TradeUP Acquisition Corp. ( UPTD ) +62% . PFSweb ( PFSW ) +48% . Bruush Oral Care ( BRSH ) +33% . Nikola Corporation ( NKLA ) +25% . ENDRA Life Sciences ( NDRA ) +24% . First Wave BioPharma ( ...
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of thre...
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) is one of today's top gainers. The company's shares are currently up 11.31% on the day to $5.61. Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rar...
2023-08-14 11:24:38 ET Eloxx Pharmaceuticals press release ( NASDAQ: ELOX ): Q2 GAAP EPS of -$1.96. As of June 30, 2023, company had unrestricted cash and cash equivalents of $4.3 million, and subsequent to quarter end, as of August 11, 2023, For further details see:...
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement of remis...
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of ...
2023-08-03 13:26:59 ET Eloxx Pharmaceuticals Inc. ( NASDAQ: ELOX ) on Thursday said it has been granted extension by Nasdaq to regain compliance with the listing rule. The listing rule requires a listed company to have at least $35 million in market value of listed securities ...
2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...
2023-07-14 08:15:40 ET First Wave BioPharma ( FWBI ) -32% . Healthcare Triangle ( HCTI ) -31% . SunCar Technology Group ( SDA ) -30% . Rockwell Medical ( RMTI ) -30% . Cadrenal Therapeutics ( CVKD ) -30% . Viasat ( VSAT ) -...
News, Short Squeeze, Breakout and More Instantly...
Eloxx Pharmaceuticals Inc. Company Name:
ELOX Stock Symbol:
NASDAQ Market:
Eloxx Pharmaceuticals Inc. Website:
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Glob...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon ...